BidaskClub cut shares of Biohaven Pharm (NYSE:BHVN) from a sell rating to a strong sell rating in a report released on Tuesday.
Several other brokerages also recently weighed in on BHVN. Zacks Investment Research upgraded shares of Biohaven Pharm from a sell rating to a hold rating in a research report on Friday, September 8th. Needham & Company LLC reissued a buy rating and set a $43.00 target price (up previously from $30.00) on shares of Biohaven Pharm in a research note on Wednesday, September 13th. Piper Jaffray Companies reissued a buy rating and set a $54.00 target price on shares of Biohaven Pharm in a research note on Tuesday, September 12th. Morgan Stanley raised their target price on shares of Biohaven Pharm from $28.00 to $47.00 and gave the company an overweight rating in a research note on Monday, September 25th. Finally, William Blair reissued an outperform rating on shares of Biohaven Pharm in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $40.80.
Shares of Biohaven Pharm (NYSE BHVN) traded up $1.42 during trading hours on Tuesday, reaching $25.36. 386,300 shares of the company traded hands, compared to its average volume of 202,643. Biohaven Pharm has a 12-month low of $17.00 and a 12-month high of $39.51.
ILLEGAL ACTIVITY WARNING: “Biohaven Pharm (BHVN) Cut to Strong Sell at BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/11/17/biohaven-pharm-bhvn-cut-to-strong-sell-at-bidaskclub.html.
In other news, insider Robert Berman sold 160,000 shares of Biohaven Pharm stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total value of $4,121,600.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Vlad Coric sold 150,000 shares of Biohaven Pharm stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.41, for a total transaction of $4,411,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 402,961 shares of company stock worth $11,098,152.
Several institutional investors and hedge funds have recently made changes to their positions in BHVN. Legal & General Group Plc acquired a new position in shares of Biohaven Pharm in the 3rd quarter worth approximately $119,000. Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharm in the 3rd quarter worth approximately $214,000. American International Group Inc. acquired a new position in shares of Biohaven Pharm in the 3rd quarter worth approximately $251,000. State of Wisconsin Investment Board acquired a new position in shares of Biohaven Pharm in the 3rd quarter worth approximately $262,000. Finally, Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharm in the 3rd quarter worth approximately $374,000. 44.03% of the stock is currently owned by institutional investors.
Biohaven Pharm Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharm and related companies with MarketBeat.com's FREE daily email newsletter.